Drugs / 99mTc sestamibi
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01347710 | Jun 2011 → Jul 2013 | coronary artery disorder | Lantheus Medical Imaging | Completed | Mixed |
| Phase 41 trial | ||||||
| Phase 4 | NCT03065218 | Oct 2016 → Feb 2021 | thyroid cancer | Medstar Health Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT02869126 | Sep 2012 → Nov 2015 | myocardial disorder | Central Hospital, Nancy, France | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc sestamibi | “99mTc sestamibi or 99mTc Tetrofosmin” NCT01347710 ↗ |
| Modality | Diagnostic / imaging agent | “Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis” NCT01347710 ↗ |
| Route | Intravenous | “First intravenous injection between 80 and 150 MBq according to patient weight” NCT02869126 ↗ |